Current Opportunities

Clinical Specialist

The Clinical Specialist will deliver Barricaid System professional education to surgeons, OR staff, and Intrinsic Therapeutics sales representatives in partnership with sales personnel and Barricaid faculty physicians to achieve great clinical outcomes for patients. The primary method of delivering this education will be through HCP (surgeon and APP) training, surgical case support, and associated activities such as patient selection and case planning. The Clinical Specialist may assist with planning, coordinating, and facilitating peer‐to‐peer and other training events within their assigned area, as well as developing and managing surgeon and APP faculty. The Clinical Specialist will assist with clinical investigation of customer complaints and Barricaid System deficiencies, and will participate in the continual improvement of training programs through contributions to training materials for both internal and external customers.

Area Vice President, Sales

Located in: Ohio, Indiana, Kentucky, Illinois, Michigan, Wisconsin, Minnesota, Missouri, Kansas, Nebraska, Iowa

Territory Managers  

Territory Managers are the lifeblood of Intrinsic and are responsible for effectively selling Barricaid within an assigned geographic territory. Barricaid is a disruptive technology that will appeal now to early adopters and innovators, with challenging discussions on reimbursement and payment, laying the ground work for broader adoption in the near-to-medium term. 

Oregon (Portland or Eugene)

Chicago, IL

New England (Boston Preferred)

Omaha, NE

Des Moines, IA

Washington, DC 

Baltimore, MD

Northern VA

Cleveland, OH

Oklahoma City, OK

Please reach out to with interest.

Intrinsic Therapeutics, Inc., a medical device company based in Woburn, Massachusetts, in collaboration with world-renowned surgeons, scientists, clinical investigators, and medical advisors, developed the Barricaid solution for patients at high risk of recurrence following lumbar discectomy surgery – the most common spinal surgery performed in the US today. Barricaid is designed to make these patients’ first spine surgery their last. Barricaid has been rigorously studied through multiple trials, including a multicenter level I RCT demonstrating superior outcomes compared to discectomy alone – leading to FDA Pre-Market Approval in 2019

If Barricaid is right for you, we can help.

Sign up to receive future updates and information on the Barricaid procedure.
  • This field is for validation purposes and should be left unchanged.

WordPress Lightbox Plugin